FindTrial
Sign In

SGI-110

DRUG8 trials

Sponsors

Astex Pharmaceuticals, Inc., Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Otsuka Pharmaceutical Co., Ltd., Italian Network for Tumor Biotherapy Foundation, Weill Medical College of Cornell University

Conditions

Acute Myeloid LeukemiaExtensive-stage Small Cell Lung CancerHepatocellular CarcinomaMetastatic Colorectal CancerMetastatic MelanomaMyeloproliferative NeoplasmsOvarian CancerPreviously Treated Metastatic Colorectal Cancer

Phase 1

Phase I/II Study of SGI-110 With Irinotecan Versus Regorafenib or TAS-102 in Metastatic Colorectal Cancer
CompletedNCT01896856
Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsPreviously Treated Metastatic Colorectal Cancer
Start: 2013-10-23End: 2019-08-26Updated: 2020-10-06
SGI-110 in Combination With an Allogeneic Colon Cancer Cell Vaccine (GVAX) and Cyclophosphamide (CY) in Metastatic Colorectal Cancer (mCRC)
CompletedNCT01966289
Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsMetastatic Colorectal Cancer
Start: 2014-04-14End: 2020-06-06Updated: 2021-03-30
Phase 1 Study of SGI-110 in Patients With Acute Myeloid Leukemia
CompletedNCT02293993
Otsuka Pharmaceutical Co., Ltd.Acute Myeloid Leukemia
Start: 2015-01-07End: 2019-05-31Updated: 2021-03-05
A Study Investigating SGI-110 in Combination With Ipilimumab in Unresectable or Metastatic Melanoma Patients
NCT02608437
Italian Network for Tumor Biotherapy FoundationMetastatic Melanoma
Start: 2015-10-31End: 2018-10-31Target: 19Updated: 2015-11-18
SGI-110 Plus Durvalumab/Tremelimumab in SCLC
CompletedNCT03085849
Catherine ShuExtensive-stage Small Cell Lung Cancer
Start: 2017-12-15End: 2018-11-26Updated: 2018-12-10

Phase 2

SGI-110 in Combination With Carboplatin in Ovarian Cancer
CompletedNCT01696032
Astex Pharmaceuticals, Inc.Ovarian Cancer
Start: 2012-09-30End: 2016-08-31Updated: 2024-08-27
SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC)
CompletedNCT01752933
Astex Pharmaceuticals, Inc.Hepatocellular Carcinoma
Start: 2012-12-31End: 2015-09-30Updated: 2024-08-27
A Phase II Study of SGI-110 in Philadelphia-Negative Myeloproliferative Neoplasms
CompletedNCT03075826
Weill Medical College of Cornell UniversityMyeloproliferative Neoplasms
Start: 2016-03-15End: 2021-03-31Updated: 2022-05-05

Related Papers

A phase <scp>II</scp> study of guadecitabine combined with irinotecan vs regorafenib or <scp>TAS</scp>‐102 in irinotecan‐refractory metastatic colorectal cancer patients
International Journal of Cancer2024-02-059 citations
Guadecitabine plus ipilimumab in unresectable melanoma: five-year follow-up and integrated multi-omic analysis in the phase 1b NIBIT-M4 trial.
2023-09-2226 citations
Guadecitabine increases response to combined anti-CTLA-4 and anti-PD-1 treatment in mouse melanoma in vivo by controlling T-cells, myeloid derived suppressor and NK cells
Journal of Experimental & Clinical Cancer Research2023-03-1825 citations
A randomized, phase II trial of oral azacitidine (CC-486) in patients with resected pancreatic adenocarcinoma at high risk for recurrence
Clinical Epigenetics2022-12-0110 citations
A feasibility study of combined epigenetic and vaccine therapy in advanced colorectal cancer with pharmacodynamic endpoint
Clinical Epigenetics2021-02-0228 citations
Methylomic Signatures of High Grade Serous Ovarian Cancer
Epigenetics2020-12-0825 citations
Safety and immunobiological activity of guadecitabine sequenced with ipilimumab in metastatic melanoma patients: The phase Ib NIBIT-M4 study.
Journal of Clinical Oncology2019-05-201 citations
Abstract CT059: Epigenetic tumor remodelling to improve the efficacy of immune checkpoint blockade: the NIBIT-M4 clinical trial
Cancer Research2018-07-012 citations
Abstract 2997: Epigenomic signatures of acquired platinum resistance in high grade serous ovarian cancer
Cancer Research2018-07-01
Abstract 4677: Integrated molecular profiles and guadecitabine response in relapsed/refractory acute myeloid leukemia
Cancer Research2017-07-01
Hypomethylating agents synergize with irinotecan to improve response to chemotherapy in colorectal cancer cells
PLoS ONE2017-04-2637 citations
Abstract CT017: A phase I study of guadecitabine (GUA) combined with irinotecan (IRI) in previously treated metastatic colorectal cancer (mCRC) patients
Cancer Research2016-07-152 citations
Epigenetic resensitization to platinum in recurrent, platinum-resistant ovarian cancer (OC) using guadecitabine (SGI-110), a novel hypomethylating agent (HMA): Results of a randomized phase II study.
Journal of Clinical Oncology2016-05-208 citations
A phase Ib study combining the second-generation DNA hypomethylating agent (DHA) guadecitabine (SGI-110) and ipilimumab in patients with metastatic melanoma: The NIBIT-M4 study.
Journal of Clinical Oncology2016-05-201 citations
Epigenome and genome alterations in platinum resistant ovarian cancer.
Journal of Clinical Oncology2015-05-20
A phase I study of investigational agent SGI-110 combined with irinotecan in previously treated metastatic colorectal cancer patients.
Journal of Clinical Oncology2015-01-201 citations
Abstract 3756: The DNA hypomethylating agent SGI-110, reverses the platinum resistance of ovarian cancer models
Cancer Research2014-10-01
Abstract IA17: Targeting the methylome for epigenetic resensitization of ovarian cancer
Clinical Cancer Research2013-10-011 citations